Loading...
XHEL
REG1V
Market cap417mUSD
Jun 18, Last price  
12.52EUR
1D
-1.26%
1Q
-31.13%
Jan 2017
23.23%
IPO
2,109.40%
Name

Revenio Group Oyj

Chart & Performance

D1W1MN
XHEL:REG1V chart
P/E
19.69
P/S
3.52
EPS
0.64
Div Yield, %
3.19%
Shrs. gr., 5y
0.69%
Rev. gr., 5y
15.91%
Revenues
110m
+5.99%
18,444,36011,456,00045,146,00029,977,00029,434,00033,281,00025,382,00025,727,00016,031,00020,250,00023,434,00026,791,00030,658,00049,474,00061,067,00078,778,00096,976,00096,576,000103,500,000109,700,000
Net income
17m
-5.93%
02,272,0002,665,000-815,000-507,0003,911,000-287,0004,338,000-694,0006,497,0005,584,0006,850,0008,103,0009,343,00013,362,00017,321,00021,753,00019,109,00018,497,00017,400,000
CFO
30m
+26.50%
01,001,0003,279,0001,956,0001,274,0004,229,000774,0005,483,0002,763,0006,811,0006,046,0007,870,00010,416,00012,489,00015,230,00021,509,00023,241,00010,862,00023,874,00030,200,000
Dividend
Apr 11, 20250.4 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Founded in 2001 and headquartered in Vantaa, Finland, Revenio Group Oyj operates as a health technology firm. This company specializes in developing, manufacturing, and distributing advanced ophthalmic diagnostic equipment and devices. These solutions are crucial for identifying and managing prevalent eye conditions such as glaucoma, macular degeneration, diabetic retinopathy, and cataracts, serving clients in Finland, across Europe, and worldwide. Their comprehensive product portfolio includes the iCare IC100 and IC200 tonometers, alongside the iCare HOME, an innovative device enabling patients to self-monitor their eye pressure. For advanced imaging, Revenio provides the iCare EIDON AF, which delivers confocal retinal imaging; the DRSplus, specifically designed for the detection of diabetic retinopathy; the iCare MAIA, a microperimeter used for precise visual field measurement; and the iCare COMPASS, facilitating fundus perimetry coupled with true-color confocal retinal images. Beyond hardware, the company also offers Oculo, a sophisticated eye care software platform. This platform seamlessly integrates functionalities for clinical communication, telehealth services, remote patient monitoring, and sophisticated data analytics.
IPO date
Jan 01, 2003
Employees
217
Domiciled in
FI
Incorporated in
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT